Tislelizumab Plus Chemotherapy for Advanced Triple-Negative Breast Cancer: The Ideal Combination
Received Date: Feb 01, 2024 / Published Date: Feb 27, 2024
Abstract
Triple-negative breast cancer (TNBC) represents a particularly aggressive subtype of breast cancer, characterized by the absence of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) expression. The lack of targeted therapies for TNBC underscores the urgent need for effective treatment strategies. Immunotherapy has emerged as a promising approach for TNBC, with the immune checkpoint inhibitor Tislelizumab showing encouraging results in combination with chemotherapy. This article reviews the rationale, clinical evidence, and future prospects of Tislelizumab plus chemotherapy for advanced TNBC.
Citation: Li X (2024) Tislelizumab Plus Chemotherapy for Advanced Triple-Negative Breast Cancer: The Ideal Combination. Breast Can Curr Res 9: 234. Doi: 10.4172/2592-4118.1000234
Copyright: © 2024 Li X. This is an open-access article distributed under theterms of the Creative Commons Attribution License, which permits unrestricteduse, distribution, and reproduction in any medium, provided the original author andsource are credited.
Select your language of interest to view the total content in your interested language
Share This Article
Recommended Journals
91勛圖 Journals
Article Tools
Article Usage
- Total views: 626
- [From(publication date): 0-2024 - Jun 17, 2025]
- Breakdown by view type
- HTML page views: 409
- PDF downloads: 217
